Additional file 2 of Effects and related mechanism of alpha-adrenergic receptor inhibitor phentolamine in a rabbit model of acute pulmonary embolism combined with shock

Additional file 2. The complete Western blot figures

Additional file 1 of Effects and related mechanism of alpha-adrenergic receptor inhibitor phentolamine in a rabbit model of acute pulmonary embolism combined with shock

Additional file 1: Figure S1. Effects of PTL dose findings experiments on average arterial pressure (MAP), average pulmonary arterial pressure (MPAP) and heart rate were shown in Sham rabbits and acute PE rabbits

Right heart hemodynamic analysis.

<p>[A, Sham (n = 10); B, UNX (n = 10); C, AV (n = 9); D, UNX+AV (n = 15)]. Values are mean±SD. RA, right atrium; RV, right ventricle; RAP, right atrial pressure; RVSP, right ventricular systolic pressure; RVEDP, right ventricular diastolic pressure; dP/dtmax, first derivative of pressure rise; dP/dtmin, first derivative of pressure decrease. *p<0.05 vs. Sham; †p<0.05 vs. UNX; ‡ p<0.05 vs. AV.</p

Echocardiographic Parameters.

<p>Values are mean±SD. LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; EF, ejection fraction; FS, fractional shortening.</p><p>*p<0.05 vs. Sham</p><p>†p<0.05 vs. UNX</p><p>‡ p<0.05 vs. AV.</p><p>Echocardiographic Parameters.</p

Biochemistry and renal function parameters.

<p>Values are mean±SD. BNP-45, rat brain natriuretic peptide-45; sCr, plasma creatinine; Cys-c, Cystatin C; GFR, glomerular filtration rate; ERPF, effective renal plasma flow; RBF, renal blood flow; RVR, renal vascular resistance; FENa, fractional excretion of sodium; UV, urine volume</p><p>*p<0.05 vs. Sham</p><p>†p<0.05 vs. UNX</p><p>‡ p<0.05 vs. AV.</p><p>Biochemistry and renal function parameters.</p

Histological features of renal tissue.

<p>[Sham (n = 10); UNX (n = 10); AV (n = 12); UNX+AV (n = 18)]. A. Periodic Acid-Schiff staining (x400) of rat with the highest proteinuria from every experimental group. B. FGS quantification. *p<0.05 vs. Sham;†p<0.05 vs. UNX;‡p<0.05 vs. AV.</p

Transthoracic echocardiography.

<p>Representative B- and M-mode images of the rats from SHAM, UNX, AV and UNX+AV groups.</p

Body weight and organ weights.

<p>Values are mean±SD. UNX, unilateral nephrectomy; AV, aortocaval fistula; BW, Body weight; HW, Heart weight; LVW, left ventricular weight; RVW, right ventricular weight; Wt, wet weight.</p><p>*p<0.05 vs. Sham</p><p>†p<0.05 vs. UNX</p><p>‡ p<0.05 vs. AV.</p><p>Body weight and organ weights.</p

A Randomized, Single-Center Double-Blinded Trial on the Effects of Diltiazem Sustained-Release Capsules in Patients with Coronary Slow Flow Phenomenon at 6-Month Follow-Up

<div><h3>Objective</h3><p>The aim of this study is to observe the chronic effects of diltiazem release capsules on patients with coronary slow flow (CSF) phenomenon.</p> <h3>Methods</h3><p>From 2004 to 2009, 80 consecutive patients with chest pain and normal coronary arteries evidenced by coronary angiography and CSF were included in this randomized, double-blind, placebo-controlled trial. CSF patterns were evaluated by the corrected TIMI frame count. Patients were randomly assigned at 1∶1 ratio to diltiazem sustained-release capsules treatment group (Dil, 90 mg twice daily) or placebo control group. Holter, liver and kidney function, treadmill exercise test, coronary angiography and left ventricular angiography were measured at baseline and after 6 months. The incidence of cardiovascular events (re-admission or progress in coronary heart disease, myocardial infarction, malignant arrhythmia or cardiac death) was evaluated during the 6 months follow up.</p> <h3>Results</h3><p>Thirty-nine patients in control and 40 patients in Dil group completed the 6 months follow-up. There was no medication induced drug withdraw during follow up. Left ventricular ejection fraction was similar between the 2 groups at baseline and during follow up. Heart rate was significantly lower in Dil group than in control group and there was no symptomatic bradycardia and II and III degree atrioventricular conduction block in both groups. Significant improvement was observed in the onset of chest pain, treadmill exercise test and coronary blood flow in Dil group while these parameters remained unchanged in control group at the end of 6 months follow up. The incidence of cardiovascular events was similar between the two groups.</p> <h3>Conclusion</h3><p>Diltiazem slow-release capsules improved coronary blood flow and alleviated angina in patients with CSF.</p> <h3>Trial Registration</h3><p>Chinese Clinical Trial Registry <a href="http://www.chictr.org/en/proj/show.aspx?proj=2090">ChiCTR-TCC-11001864</a></p> </div

Gross heart morphology showing ventricular enlargement and cardiac hypertrophy (of rat hearts) in the AV group, especially (of rat hearts) in the UNX+AV group.

<p>Gross heart morphology showing ventricular enlargement and cardiac hypertrophy (of rat hearts) in the AV group, especially (of rat hearts) in the UNX+AV group.</p